A phase IB clinical trial of 15 Gy HDR brachytherapy followed by hypofractionated/SBRT in the management of intermediate-risk prostate cancer-Reference-Cited by-同舟云学术

A phase IB clinical trial of 15 Gy HDR brachytherapy followed by hypofractionated/SBRT in the management of intermediate-risk prostate cancer

Published:2020-05 Issue:3 Volume:19 Page:282-289
ISSN:1538-4721
Container-title:Brachytherapy
language:en
Short-container-title:Brachytherapy

Author:

Den Robert B.,Greenspan Jacob^ORCID,Doyle Laura A.,Harrison Amy S.,Peng Cheng,Williams Noelle L.,Lallas Costas D.,Trabulsi Edouard J.,Gomella Leonard G.,Hurwitz Mark D.,Leiby Benjamin,Dicker Adam P.

Publisher

Elsevier BV

Subject

Radiology, Nuclear Medicine and imaging,Oncology

Reference32 articles.

1. Dosimetric comparison between treatment plans of patients treated with low-dose-rate vs. high-dose-rate interstitial prostate brachytherapy as monotherapy: Initial findings of a randomized clinical trial;Major;Brachytherapy,2017

2. Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate;Sathya;J Clin Oncol,2005

3. Long-term results of a randomized trial comparing iridium implant plus external beam radiation therapy with external beam radiation therapy alone in node-negative locally advanced cancer of the prostate;Dayes;Int J Radiat Oncol Biol Phys,2017

4. Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer;Hoskin;Radiother Oncol,2012

5. Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Statistical methods and data visualisation of patient-reported outcomes in early phase dose-finding oncology trials: a methodological review;eClinicalMedicine;2023-10

2. Comparison of four-year toxicities and local control of ultra-hypofractionated vs moderate-hypofractionated image guided prostate radiation with HDR brachytherapy boost: A phase I-II single institution trial;Clinical and Translational Radiation Oncology;2023-05

3. Safety of accelerated hypofractionated whole pelvis radiation therapy prior to high dose rate brachytherapy or stereotactic body radiation therapy prostate boost;Radiation Oncology;2022-01-20

4. Complications and side effects of high-dose-rate prostate brachytherapy;Brachytherapy;2021-09

5. Evolving Brachytherapy Boost in Prostate Cancer in the Era of Hypofractionation;International Journal of Radiation Oncology*Biology*Physics;2020-11